ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) ("Phreesia†or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2025. "I am very proud of our team's strong execution in the fiscal third quarter, which is reflected throughout this letter from our revenue and profit results to product updates and client stories,†said CEO and Co- Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the ...

Financial Performance - Total revenue for Q3 Fiscal 2026 was $120.3 million, representing a 13% year-over-year increase[7] - Net income for the quarter was $4.3 million, compared to a net loss of $14.4 million in the same period last year[7] - Adjusted EBITDA for the quarter was $29.1 million, compared to $9.8 million in the same period last year[7] - Total revenues for the three months ended October 31, 2025, were $120.3 million, a 12.5% increase from $106.8 million in the same period of 2024[28] - Net income for the three months ended October 31, 2025, was $4.3 million, compared to a net loss of $14.4 million in the same period of 2024[28] - Operating income improved to $3.7 million from a loss of $13.8 million year-over-year[28] - Adjusted EBITDA for the three months ended October 31, 2025, was $29,149,000, compared to $9,769,000 for the same period in 2024, representing a significant increase[41] - Free cash flow for the three months ended October 31, 2025, was $8,801,000, compared to $1,603,000 for the same period in 2024, demonstrating improved cash generation capabilities[44] - Net income for the three months ended October 31, 2025, was $4,271,000, a significant improvement from a net loss of $14,403,000 in the same period of 2024[41] Client Metrics - Average number of healthcare services clients (AHSCs) increased to 4,520, up 7% year-over-year[7] - The company expects AHSCs for fiscal 2026 to be approximately 4,515, including 15 AHSCs from the AccessOne acquisition[12] - The average number of healthcare services clients (AHSCs) increased to 4,520 in the three months ended October 31, 2025, up from 4,237 in the same period of 2024, indicating growth in client acquisition[48] - Total revenue per AHSC for the three months ended October 31, 2025, was $26,622, compared to $25,207 for the same period in 2024, reflecting a year-over-year increase of 5.6%[48] Revenue Outlook - The company updated its revenue outlook for fiscal 2026 to a range of $479 million to $481 million, including approximately $7.5 million from AccessOne[10] - For fiscal 2027, the company anticipates revenue in the range of $545 million to $559 million, a 14-16% increase over fiscal 2026[13] Acquisition and Investment - The AccessOne acquisition was completed for approximately $160 million, enhancing the company's financing solutions for healthcare receivables[4] - Research and development expenses were $29.5 million, consistent with $29.3 million in the prior year, indicating stable investment in innovation[28] - Capitalized internal-use software development costs for the three months ended October 31, 2025, were $3,395,000, compared to $3,566,000 in the same period of 2024, indicating a stable investment in technology[44] Cash and Assets - Cash and cash equivalents as of October 31, 2025, were $106.4 million, an increase of $22.2 million from January 31, 2025[7] - Cash and cash equivalents increased to $106.4 million as of October 31, 2025, compared to $81.7 million at the end of the previous year[32] - Total current assets rose to $240.9 million, a 18.5% increase from $203.3 million as of January 31, 2025[26] Liabilities and Expenses - Total liabilities decreased to $103.1 million from $123.6 million, reflecting a reduction of 16.6%[26] - GAAP operating expenses for the three months ended October 31, 2025, totaled $89,427,000, down from $96,873,000 in the same period of 2024, indicating cost management efforts[46] - Stock-based compensation expense for the three months ended October 31, 2025, was $15,959,000, slightly lower than $16,525,000 in the same period of 2024, reflecting a controlled approach to compensation[46] Payment Metrics - Patient payment volume reached $1,181 million in the three months ended October 31, 2025, compared to $1,081 million in the same period of 2024, showing a growth of 9.3%[51] - The payment facilitator volume percentage increased to 85% in the three months ended October 31, 2025, up from 81% in the same period of 2024, indicating a higher reliance on the payment facilitation services[51]

分组1 - U.S. stock futures are trading higher, indicating a positive market sentiment for the day [1] - Toll Brothers Inc. is expected to report quarterly earnings of $4.89 per share on revenue of $3.30 billion, with shares rising 0.1% to $139.00 in after-hours trading [2] - Phreesia Inc. is projected to post quarterly earnings of 2 cents per share on revenue of $120.05 million, with shares increasing 0.5% to $20.39 in after-hours trading [2] - Meihua International Medical Technologies Co., Ltd. announced its delisting from Nasdaq, resulting in a 16.5% drop in shares to $11.71 during after-hours trading [2] - Ooma Inc. is anticipated to report quarterly earnings of 22 cents per share on revenue of $67.59 million, with shares gaining 1.2% to $11.88 in after-hours trading [2] - Compass Minerals International Inc. is expected to report a quarterly loss of 23 cents per share on revenue of $223.50 million, with shares closing up 0.8% at $20.28 [2]

Phreesia, Inc. (NYSE:PHR) will release earnings results for the third quarter after the closing bell on Monday, Dec. 8.Analysts expect the Wilmington, Delaware-based company to report quarterly earnings at 24 cents per share, up from 4 cents per share in the year-ago period. The consensus estimate for Phreesia's quarterly revenue is $120.03 million, compared to $106.8 million a year earlier, according to data from Benzinga Pro.On Sept. 4, Phreesia posted mixed results for the second quarter.Phreesia shares ...

Phreesia, Inc. (NYSE:PHR) will release earnings results for the third quarter after the closing bell on Monday, Dec. 8.Analysts expect the Wilmington, Delaware-based company to report quarterly earnings at 24 cents per share, up from 4 cents per share in the year-ago period. The consensus estimate for Phreesia's quarterly revenue is $120.03 million, compared to $106.8 million a year earlier, according to data from Benzinga Pro.On Sept. 4, Phreesia posted mixed results for the second quarter.Phreesia shares ...

Core Insights - Phreesia, Inc. is set to release its quarterly earnings on December 8, 2025, with analysts estimating an EPS of $0.24 and revenue of approximately $120 million [1][5] - The projected revenue of $120.13 million represents a 12.5% increase compared to the same quarter last year, indicating positive growth for the company [2][5] - The company's price-to-sales ratio is 2.72, and the enterprise value to sales ratio is 2.51, suggesting efficient capital use [3] - Phreesia has a low debt-to-equity ratio of 0.016, indicating minimal reliance on debt financing, and a current ratio of 2.12, reflecting a strong ability to cover short-term liabilities [3] Financial Metrics - Analysts estimate an EPS of $0.24 for the upcoming earnings report [5] - Projected quarterly revenue is $120.13 million, marking a 12.5% year-over-year increase [2][5] - The price-to-sales ratio of 2.72 indicates investors are willing to pay $2.72 for every dollar of sales [3] - The enterprise value to sales ratio of 2.51 suggests efficient capital utilization [3] Market Expectations - The upcoming earnings report and management discussion will be critical for determining future earnings expectations and stock price movements [4] - Investors are closely monitoring whether Phreesia will exceed earnings expectations, as a positive earnings report could lead to a stock price increase [4]

Core Insights - Wall Street analysts expect Phreesia (PHR) to report quarterly earnings of $0.00 per share, reflecting a year-over-year increase of 100% [1] - Revenue projections for Phreesia are set at $120.13 million, which represents a 12.5% increase from the same quarter last year [1] - There has been a 50% upward revision in the consensus EPS estimate over the last 30 days, indicating a significant reassessment by analysts [1] Revenue Estimates - Analysts estimate 'Revenue - Subscription and related services' to be $55.44 million, marking a 12.3% increase from the previous year [4] - 'Revenue - Network solutions' is projected to reach $37.46 million, indicating a 14.5% year-over-year change [4] - 'Revenue - Payment processing fees' is expected to be $27.25 million, reflecting a 10.3% increase compared to the prior year [5] Client and Volume Metrics - The average number of healthcare services clients is anticipated to be 4,530, up from 4,237 in the same quarter last year [5] - The consensus estimate for 'Patient payment volume' is $1.16 billion, compared to $1.08 billion from the previous year [5] - Analysts project a 'Payment facilitator volume percentage' of 81.3%, slightly up from 81.0% year-over-year [6] Stock Performance - Over the past month, Phreesia shares have declined by 10.6%, while the Zacks S&P 500 composite has seen a minor decrease of 0.1% [6] - Phreesia holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the overall market in the near future [6]

Core Viewpoint - The market anticipates that Phreesia (PHR) will report a year-over-year increase in earnings driven by higher revenues when it releases its quarterly results for the period ending October 2025 [1] Earnings Expectations - The earnings report is scheduled for December 8, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2] - The consensus estimate for Phreesia's quarterly earnings is projected at $0.00 per share, reflecting a year-over-year increase of +100%, with revenues expected to reach $120.13 million, a 12.5% increase from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised 50% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Phreesia is significantly higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1,100.00%, suggesting a bullish outlook from analysts [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Phreesia currently holds a Zacks Rank of 2, reinforcing the likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Phreesia was expected to incur a loss of $0.07 per share but instead reported earnings of $0.01, resulting in a surprise of +114.29% [13] - Over the past four quarters, Phreesia has consistently beaten consensus EPS estimates [14]

Company Overview - Phreesia, Inc. is a healthcare technology company focused on patient intake and engagement, aiming to enhance the patient experience and healthcare outcomes [1] Financial Performance - Phreesia's Return on Invested Capital (ROIC) is 0.52%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 7.01%, indicating inefficiency in capital utilization [2][6] - The ROIC to WACC ratio for Phreesia is 0.074, further highlighting its challenges in generating returns above its cost of capital [2][6] Peer Comparison - Health Catalyst has a negative ROIC of -16.99% against a WACC of 6.57%, resulting in a ROIC to WACC ratio of -2.59, indicating worse performance than Phreesia [3] - Veracyte has a ROIC of 0.99% and a WACC of 13.50%, with a ROIC to WACC ratio of 0.073, suggesting it also struggles to generate sufficient returns, but is noted for having the highest growth potential among peers [4][6] - Accolade, Castle Biosciences, and Personalis all report negative ROICs of -31.79%, -4.28%, and -30.51% respectively, with their WACCs at 10.94%, 8.83%, and 11.72%, indicating significant challenges in generating returns above their cost of capital [5]

Core Insights - Conestoga Capital Advisors reported strong equity market performance in Q3 2025, with their Micro-Cap Composite returning 11.7% net-of-fees, while the Russell Microcap Growth Index returned 19.9% [1] Company Overview: Phreesia, Inc. (NYSE:PHR) - Phreesia, Inc. is a SaaS-based software and payment platform provider for the healthcare sector, headquartered in Wilmington, Delaware [2] - As of October 17, 2025, Phreesia's stock closed at $22.29 per share, with a market capitalization of $1.335 billion [2] Financial Performance - Phreesia reported a 15% year-over-year revenue growth in Q2 2026, totaling $117.3 million, with EBITDA margins expanding to 19% [3][4] - The company raised its full-year profitability outlook following better-than-expected Q2 results [3] Recent Developments - Phreesia announced the acquisition of AccessOne for $160 million, which is expected to add $35 million in revenue and $11 million in EBITDA [3] - The acquisition raised some investor concerns as it represents an expansion into a new area within their payments platform [3] Market Position - Phreesia was held by 28 hedge fund portfolios at the end of Q2 2025, indicating stable interest among institutional investors [4] - Despite its potential, the company is viewed as having less upside compared to certain AI stocks, which are considered to carry less downside risk [4]